Showing results (21-30 of 62) with videos related to
Sort By:
Pageof 7
American Journal of Clinical Pathology|October 16, 2019
Toward Improving Practices for Submission of Diagnostic Tissue Blocks for National Cancer Institute Clinical TrialsHala Makhlouf, Mark A Watson, Heather A Lankes, et al.Gynecologic Oncology|January 18, 2017
A phase 2 study of alisertib (MLN8237) in recurrent or persistent uterine leiomyosarcoma: An NRG Oncology/Gynecologic Oncology Group study 0231DDavid M Hyman, Michael W Sill, Heather A Lankes, et al.Gynecologic Oncology|November 1, 2011
A phase II evaluation of lapatinib in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma: a gynecologic oncology group studyAgustin A Garcia, Michael W Sill, Heather A Lankes, et al.Gynecologic Oncology|June 20, 2012
Phase II evaluation of dasatinib in the treatment of recurrent or persistent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group studyRussell J Schilder, William E Brady, Heather A Lankes, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 11, 2020
Randomized Phase II Trial of Nivolumab Versus Nivolumab and Ipilimumab for Recurrent or Persistent Ovarian Cancer: An NRG Oncology StudyDmitriy Zamarin, Robert A Burger, Michael W Sill, et al.Gynecologic Oncology|May 10, 2017
Multiplex profiling identifies distinct local and systemic alterations during intraperitoneal chemotherapy for ovarian cancer: An NRG Oncology/Gynecologic Oncology Group StudyShannon Grabosch, George Tseng, Robert P Edwards, et al.Obstetrics and Gynecology|November 7, 2024
Optimization of Timing for Risk-Reducing Salpingectomy and OophorectomyKathryn P Pennington, Stephanie L Pugh, Warner Huh, et al.Gynecologic Oncology|March 11, 2023
Fear of recurrence, emotional well-being and quality of life among long-term advanced ovarian cancer survivorsKathryn Osann, Lari Wenzel, Chelsea McKinney, et al.Gynecologic Oncology|July 7, 2023
A phase 2 study of dasatinib in recurrent clear cell carcinoma of the ovary, fallopian tube, peritoneum or endometrium: NRG oncology/gynecologic oncology group study 0283Roisin E O'Cearbhaill, Austin Miller, Robert A Soslow, et al.Gynecologic Oncology|December 29, 2016
A phase II evaluation of ixabepilone in the treatment of recurrent/persistent carcinosarcoma of the uterus, an NRG Oncology/Gynecologic Oncology Group studyCarolyn K McCourt, Wei Deng, Don S Dizon, et al.Pageof 7